Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Was it replaced by positive BE data? Nope! Just another delay...
I can assure you it won't be coming from a hat...
Oh, of course, while filling his pockets merrily along the way. Can't be denied with these non-arms length transactions. Board is delusional, which is usually the case with OTC companies. Heck, that is almost true with all boards, regardless of size.
Did he also cry out for someone to please manufacture Trimipramine cuz the world is in more dire need than Nasrat's pockets?
Maybe cuz no one needs or wants it.
Teva had to give it up to pursue their acquisition. Tech had zero say.
You didn't stutter on this yet, but you will as the dates pass by.
Always fun to read your posts. Regardless, of how the stock is doing, the posts consistently bring on some good laughter.
We just bought Trimipramine. That won't do it? Lol
This is potential over a series of years.
Trimipramine!! Hahahaha! Rofl
You do realize the nation is on vacation on Monday? :)
I am talking sequential, not y/y. As you say, facts are facts and not malleable.
Dec 16: $2.3M
Sep '16: $2.7M
Jun '16: $3.3M
Mar '16: $5.2N
Dang those stubborn facts! A whole year of sliding revenue. When new sales products are added sequential quarters are more important than prior year to show momentum. For the last 2 quarters, "delayed shipments and quotas have been the scape goats. This is a piss poor excuse, plain and simple.
Lots of talk, no action. Trimipramine might cause a rounding adjustment each quarter if we go to the next decimal. Woohoo!
It has dropped during, but drops more consistently after. With no pending SequestOx news until well after the conference and falling generic sales quarter after quarter this may very well be a challenging call. Knowing Nasrat's history of opening his mouth and the stock dropping, history can be a very good guide here.
Nothing he can do on Percocet filing. Crappy Trimipramine probably counts as ANDA for the quarter. LOL
Next step will be selling generic Flintstone vitamins. Wait. That would actually have a much higher revenue stream than Trimipramine.
I understand your frustration. I really do. I think you are looking a little too deep here. The exclusions have nothing to do with bioequivalence. Simple criteria is simply not being met to have data included. This could easily be people people simply not taking the pills at the right time, eating when taking the pill, perhaps some tried to inject it, etc. With this small of study we want to ensure the criteria is met so we can analyze the data appropriately. If data collected is bogus, the analysis will follow suite. The only red flag for me is that we have another freaking delay. Camargo is ensuring exact execution of the subjects inclusion/exclusion criteria that is holding up the process.
Now I personally think that this will also delay the SequestOx submission later this year to move to Q1 2018 assuming all goes well with BE & dosing studies.
Not at all. If you can't get all of your subjects to fit the criteria then you simply wait until then. That is all there is to it. This has zero to do with the results.
The question was whether Elite has visibility to the data, not around inclusion criteria. I am not concerned about these exclusions as that is protocol.
I think they are blind to the data until the end of the study. I am not an expert here, but that is my understanding through other companies that have explained their visibility for studies.
I am not close to study granular details, but imagine that Elite can only see at this point subject acceptance criteria. I can't imagine they have statistical data at this point. I think Nasrat is still running with earlier hypothesis that we are BE and the recent modification should lower Tmax, but don't think he has any hard data to back that up yet until after the study is complete in July-ish.
All depends on whether ELTP is blind to the details of the study.
Nope. CC will come and go without results. They will pump as much good news and give another dump afterwards so can avoid during Q&A & business update. This has been the consistent pattern.
Or could tack on another month. End of July is still July.
1 million traded in under 10 minutes. Woohoo! All due to pure competence.
How would we avoid the dosing studies? I don't think that is possible.
Thank goodness we had good news of Trimipramine this week. Not sure what investors would do otherwise.
Lol And there are those that read today's PR as positive. Hahaha!
I am guessing Nasrat knew this right around time of 20% dividend. Go figure. What other bad news is being hid?
Or they are just stalling and giving that perception. Yes, perhaps.
Gotta hand it to management. They are learning. I expected this PR tomorrow night.
Poor execution and management. Nothing worse than having direct report tell you they can't deliver on day deliverable is due. They should have known this problem for weeks and are coming out today with the delay?
OTC quality at its finest.
Are you saying they are cherry picking their recruits? Potentially extending the trial because results aren't up to snuff and looking for specific recruits that will provide the results they seek?
Spellcheck would be key for the press release. Lol
Ha! I agree with you here. The transcriptions are always absolutely awful. Sometimes humorous, but seems like they would have human intervention or better tech at this point. Lousy at best.
Haha! The bell tolls on the hour. Last I read there were 13, but it was in the fiction section.
Thanks for sharing. Wasn't aware they were on Beer's list.
Plenty of other options, which is why this revenue is so paltry. How about SNRIs, NDRIs, or other trycyclic antidepressants? Plenty of options.
Yep, cause the FDA is keenly aware that there are no other anti-depressant options other than Trimipramine.
CEO could care less about retail shareholders. Latest round of preferred stock creation with 20% dividend and side dealings with Mikah validate this.
Nice. Ha!